Keros Therapeutics, Inc.
KROS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $592,644 | $1,170,817 | $1,212,074 | $1,365,267 |
| - Cash | $559,931 | $331,147 | $279,048 | $230,042 |
| + Debt | $18,861 | $14,444 | $13,266 | $1,093 |
| Enterprise Value | $51,574 | $854,114 | $946,292 | $1,136,318 |
| Revenue | $3,550 | $151 | $0 | $20,100 |
| % Growth | 2,251% | – | -100% | – |
| Gross Profit | $3,550 | $151 | $0 | $20,100 |
| % Margin | 100% | 100% | – | 100% |
| EBITDA | -$185,824 | -$152,177 | -$104,004 | -$56,351 |
| % Margin | -5,234.5% | -100,779.5% | – | -280.4% |
| Net Income | -$187,353 | -$152,992 | -$104,679 | -$58,744 |
| % Margin | -5,277.5% | -101,319.2% | – | -292.3% |
| EPS Diluted | -5 | -5.2 | -4.15 | -2.52 |
| % Growth | 3.8% | -25.3% | -64.7% | – |
| Operating Cash Flow | -$160,869 | -$124,508 | -$70,062 | -$62,148 |
| Capital Expenditures | -$1,931 | -$2,464 | -$1,241 | -$1,024 |
| Free Cash Flow | -$162,800 | -$126,972 | -$71,303 | -$63,172 |